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Abstract
Background: Apparent emerging artemisinin-resistant Plasmodium falciparum malaria in Southeast Asia requires
development of practical tools to monitor for resistant parasites. Although in vitro anti-malarial susceptibility tests
are widely used, uncertainties remain regarding interpretation of P. falciparum field isolate values.
Methods: Performance parameters of the W2 P. falciparum clone (considered artemisinin “sensitive”) were
evaluated as a reference for the HRP-2 immediate ex vivo assay. Variability in W2 IC50s was assessed, including
intra- and inter-assay variability among and between technicians in multiple experiments, over five freeze-thaw
cycles, over five months of continuous culture, and before and after transport of drug-coated plates to remote field
sites. Nominal drug plate concentrations of artesunate (AS) and dihydroartemisinin (DHA) were verified by LC-MS
analysis. Plasmodium falciparum field isolate IC50s for DHA from subjects in an artemisinin-resistant area in
Cambodia were compared with W2 susceptibility.
Results: Plate drug concentrations and day-to-day technical assay performance among technicians were important
sources of variability for W2 IC50s within and between assays. Freeze-thaw cycles, long-term continuous culture, and
transport to and from remote sites had less influence. Despite variability in W2 susceptibility, the median IC50s for
DHA for Cambodian field isolates were higher (p <0.0001) than the W2 clone (3.9 nM), both for subjects with
expected (less than 72 hours; 6.3 nM) and prolonged (greater or equal to 72 hours; 9.6 nM) parasite clearance times
during treatment with artesunate monotherapy.
Conclusion: The W2 reference clone improved the interpretability of field isolate susceptibility from the immediate
ex vivo HRP-2 assay from areas of artemisinin resistance. Methods to increase the reproducibility of plate coating
may improve overall assay interpretability and utility.
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Background
Artemisinins are the latest class of safe, effective anti-
malarial drugs to be threatened by drug resistance [1,2].
Assessment of artemisinin therapeutic efficacy is essen-
tial for health policy decision making for malaria control
programmes, but an operational definition of artemisinin
resistance remains elusive. In vitro/ex vivo parasite drug
susceptibility tests are widely used, but uncertainties
remain regarding the use and interpretation of such
systems to evaluate field isolates for artemisinin resist-
ance, particularly when used in isolation, without clin-
ical correlation. The most commonly used in vitro/
ex vivo susceptibility assays, including histidine-rich
protein 2 enzyme linked immunosorbent assay (HRP-2
ELISA) [3,4], schizont maturation [3,5], radioisotopic
uptake [6,7], and most recently the SYBR Green I
method [8-11], are subject to numerous sources of
variability. Differences in assay methods, laboratory
conditions, parasite strain susceptibility phenotypes,
and technical performance can confound interpretation
and affect comparability of results [12-14], especially
across different laboratories. In addition, drug proper-
ties, including solubility and mechanism of action can
have method-dependent effects on data analysis and
interpretation [15].
The need for harmonized in vitro/ex vivo drug suscep-
tibility monitoring to be employed by a network of re-
gional reference laboratories has been well articulated
[13]. A key recommendation supporting this effort is the
use of standardized Plasmodium falciparum reference
clones to provide context for variability among the sev-
eral assay systems. Quantifying inherent assay variability
and establishing a drug susceptibility reference range are
essential for laboratory-adapted clones to permit mean-
ingful data comparisons. Just as in clinical laboratories,
establishing reference ranges can account for local vari-
ance attributable to technical performance and method-
ology issues. Reference ranges can then be used to
classify susceptibilities of P. falciparum field isolates
obtained from different laboratories.
Since 2004, AFRIMS has used an HRP-2 ELISA
method for drug resistance testing because of its high
sensitivity, particularly for the artemisinins, when used
in immediate ex vivo assays of P. falciparum field iso-
lates from low-transmission endemic areas, such as
Thailand and Cambodia [3,16]. AFRIMS selected the
“Indochina” W2 clone as a reference for its genetic simi-
larity to potential field isolates, its drug susceptibility
profile, and ease of culture adaptation.
W2 drug susceptibility was measured by 50% inhibi-
tory concentrations (IC50) against dihydroartemisinin
(DHA) and artesunate (AS), as well as key long-acting
agents, including mefloquine (MQ) and chloroquine
(CQ), which were used as drug susceptible and resistant
controls respectively. Experiments were conducted to
systematically assess potential sources of assay variabil-
ity. Variations in IC50s were quantified, and the suscep-
tible ranges of W2 for DHA and AS were established in
the HRP-2 assay. The susceptibility range for W2 clones
used as quality controls was also compared against P.
falciparum field isolates from an area of suspected arte-
misinin resistance in western Cambodia [17].
Methods
Plasmodium falciparum W2 clone cultivation
Plasmodium falciparum reference clone W2, maintained
in culture continuously at AFRIMS and cryopreserved in
a glycerolyte solution, was recovered as previously
described [18]. Continuous cultures were grown using a
modified Trager and Jensen method [19]. Briefly, para-
sites were maintained in RPMI-1640 medium containing
25 mM HEPES, 25 mM sodium bicarbonate, 5% human
O+ erythrocytes, 10% pooled AB+ serum and 0.1 mg/mL
gentamycin at 37°C with 5% CO2, 5% O2, and 90% N2.
Human erythrocyte and pooled serum were obtained
from the National Blood Center, Thai Red Cross Society.
Parasites were synchronized utilizing 5% D-sorbitol as
previously described [20]. Two sorbitol treatments were
performed with a 64-hour interval to provide the highest
proportion of synchronized parasites, and parasite cul-
ture was maintained for 48 hours after synchronization
prior to conducting the drug susceptibility assay.
Preparation of drug-coated plates
Anti-malarial drugs were coated onto 96-well plates in
triplicate to assess W2 clone variability, with the excep-
tion of the drug stability and field isolate experiments
where duplicate wells were used. Drug compounds were
dissolved in 70% ethanol to make 1 mg/ml stock solu-
tions, and then diluted to appropriate concentration by
sterile distilled water. Three-fold serial drug dilutions
were performed on plates which then air-dried overnight
in a biosafety cabinet to reach final nominal drug con-
centrations (after 200 μL of sample were added) ranging
from 20 to 0.027 ng/ml for DHA and AS, 200 to
0.274 ng/ml for MQ and 2,000 to 2.74 ng/ml for CQ.
The top row of each plate served as a drug-free control.
Molecular weight of DHA, AS, MQ (HCl) and CQ
(2H3PO4) were 284.35, 384.42, 414.78, and 515.92 g/
mole, respectively. Dried plates were stored at 4°C.
Plates were used within 2 months of preparation. Plate
preparation and storage methodology was based on pre-
liminary experiments establishing reproducibility of
IC50s under these conditions.
Analysis of plate drug concentration by LC/MS
Drug substance from the starting wells of three lots of
three dry drug-coated plates selected for quality control
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analysis was recovered to determine accuracy of the
nominal starting concentration of 4 ng of AS or DHA in
each well. The solvent for AS and DHA used for LC/MS
analysis (100 μL of 50% acetonitrile) was added to each
starting well to obtain a final concentration 40 ng/ml for
both AS and DHA. The coated drug was dissolved in
the solution by manually agitating the plate for 5 min
with complete dissolution. The resulting solution was
then transferred to an auto-sampler vial for LC/MS ana-
lysis, and 5 μL of the solution was injected directly into
the system for quantification.
Plate drug concentrations for AS and DHA for differ-
ent coated plates lots were verified by LC/MS analysis
using a previously described bio-analytical method [21].
Briefly, AS and DHA were analysed using the LC/MS
system consisting of a reversed phase column (XTerra
MS C18, 3.5 μm, 2.1 x 50 mm, Waters Corporation,
MA, USA) and pre-column of the same material (2.1 x
10 mm) connected to the Alliance 2695 Liquid Chroma-
tography system equipped with a single quadrupole
Micromass ZQ (MM1) Mass Spectrometry detector
(Waters Corporation) in the positive electrospray
ionization mode and single ion recording. The analytes
(AS and DHA) were eluted from the column with
6.25 mM ammonium acetate buffer pH 4.5 and aceto-
nitrile gradient from 20% to 40% in 9 min at the flow
rate of 0.4 ml/min. The ammonium-adducts of DHA
and AS were detected at the m/z ratios of 302 and 402
and eluted near 5 and 6 min, respectively, with total ana-
lysis time of 12 min. Resulting concentrations were
extrapolated from a standard curve of DHA or AS
respectively.
HRP-2 ELISA drug susceptibility testing
Synchronized W2 parasites with >90% ring forms were
diluted to 0.5% parasitaemia with 1.5% haematocrit in
0.5% Albumax RPMI-1640, and transferred to drug-
coated plates. Plates were incubated at 37°C with 5%
CO2, 5% O2, and 90% N2 for 72 hours. For field isolates,
blood samples with ≤0.5% parasitaemia were transferred
to drug-coated plates without culture adaptation
(ex vivo), and those with >0.5% parasitaemia were
diluted to 0.2-0.5% before transferring. Plates were incu-
bated at 37°C using a candle jar, instead of mixed gas, to
create favourable conditions, and parasite growth inhib-
ition after 72 hours was analysed by HRP-2 ELISA assay,
as previously described [3].
Due to the high sensitivity of the HRP-2 ELISA assay,
in order to obtain IC50 values, samples were diluted be-
fore performing the ELISA. To estimate parasite growth
rate, samples were collected from the untreated wells at
0, 24, 48 and 72 hours, then serially diluted and analysed
by HRP-2 ELISA assay. The serial dilution providing the
greatest increase in OD values between 0 and 72 hours
was then used as the dilution factor for the parasite cul-
ture samples in the HRP-2 ELISA. HRP-2 protein ODs
were plotted against drug concentrations and IC50s were
analysed using ICEstimator 1.2 by non-linear regression,
to estimate the sigmoidal dose response curve as previ-
ously described [22,23]. For the purposes of analysing
sources of variability in the W2 clone experiment (with
the exception of the drug stability experiment), three in-
dividual IC50 values were estimated from each of the
triplicate serial drug dilutions on the plate, while IC50
values from field isolates and the drug stability experi-
ment were calculated by averaging ODs from duplicate
serial dilutions.
Assessment of sources of assay variability
In vitro drug susceptibility testing of the W2 parasite
was conducted systematically in order to determine vari-
ability of the following factors: (1) variability within an
HRP-2 assay found between wells of drug plates and be-
tween different drug plates run by a single technician on
a single day (‘Intra-assay’ variability); (2) variability be-
tween assays conducted on five different days by the
same technician (‘Inter-assay’); (3) Technician perform-
ance assessed as the variability between technicians in
overall median IC50 values; (4) variability introduced by
repeated parasite freeze/thaw cycles; (5) variability due
to long-term parasite culture (Longevity); and, (6) Stabil-
ity of drug-coated plates during transport to/from and
storage at field sites, assessed as difference in IC50s ana-
lysed on drug-coated plates before and after transport to
field sites. During transport to and from the field sites,
plates were stored on ice packs (2-6°C) en route, with an
average of eight hours transport time, and stored in a re-
frigerator (2-6°C) at the field site.
Comparative drug susceptibility of W2, 3D7 and D6
clones
In order to establish comparability with previous pub-
lished reports of parasite clone susceptibility phenotypes,
in vitro susceptibility results for W2, 3D7 and D6 against
DHA, AS, MQ and CQ (eight replicates each) were
compared.
Artemisinin susceptibility of field Plasmodium falciparum
isolates against reference W2 clone
Clinical isolates were obtained from patients enrolling in
a previously reported clinical trial of artesunate mono-
therapy in Tasanh, Cambodia [17]. Immediate ex vivo
(IEV) drug susceptibility testing without culture adapta-
tion was performed on 125 evaluable P. falciparum iso-
lates from an area of known artemisinin resistance using
the methods above. Isolates were considered evaluable if
an IC50 could be determined using the IEV method. In
each 12-plate coating lot used for field parasite analysis,
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two to seven drug plates were randomly selected for W2
drug susceptibility testing either before or after transport
to field. IEV IC50 values of field isolates were compared
with W2 IC50 values.
Statistical analysis
Geometric mean, median, range and interquartile values,
and% CV for IC50 values were calculated. To define the
normal susceptible performance range of W2 for DHA
and AS, outlier IC50 values, as determined by Grubbs' test,
were excluded and the range of minimum and maximum
IC50 values were defined. Kruskal-Wallis and Mann–
Whitney U tests were used to analyse the differences in
technician performance and compare the IC50 values of
the W2 clone to field parasite isolates. To assess drug sta-
bility, the Wilcoxon matched-pair test was used to com-
pare W2 IC50 values on drug-coated plates before and
after transport to field sites. Statistical significance was
defined as p <0.05. For multiple comparison analysis, the
cut-off p-value was adjusted for the number of compari-
sons by using the Bonferroni correction. Statistical analysis
was performed using Graphpad Prism for Windows, ver-
sion 5 (Graphpad Software, Inc, San Diego, CA, USA).
Results
Assessment of sources of assay variability
Three technicians performed IC50 assays on the W2
clone concurrently using triplicate serial dilutions on five
different plates for each drug assayed to obtain 15 indi-
vidual IC50 values (Figure 1). The% CV for “intra-assay”
variability from these individual experiments was con-
sistent between technicians, ranging from 8.2%-10.9%
for DHA (Figure 1) and 8.0%-15.9% for AS.
Each technician repeated this experiment on a total of
five occasions to assess the day-to-day variability of IC50
values (inter-assay variability). The% CV values for inter-
assay variability ranged from 16.9% to 22.8% for DHA
(Figure 1) and 32.3% to 36.1% for AS. Median IC50
values for the three technicians ranged from 3.6 to 4.3
nM with an overall% CV of 22.7 for DHA (Figure 1) and
3.6 to 5.4 nM (% CV= 36.2 overall) for AS. There was a
statistically significant difference in IC50 values obtained
from each of the three technicians for both DHA and
AS (p < 0.0001 by Kruskal-Wallis test). A significant dif-
ference in median IC50 values was found between tech-
nician 1 and technician 2, as well as technician 1 and 3
(p < 0.0001, Mann–Whitney U tests), but not between
technician 2 and 3 (p = 0.84).
IC50 assays were conducted following parasite freeze-
thaw for up to five cycles (Figure 1). Median IC50 values
in five separate freeze/thaw experiments were 2.5-4.1
nM for DHA (% CV= 27.8) and 2.7-3.9 nM for AS (%
CV=22). To assess variability due to long-term parasite
culture, IC50 values were evaluated monthly over a five-
month period using a continuously growing W2 culture
(Figure 1). During this time, median IC50 values
Figure 1 HRP-2 ELISA assay variability for the W2 Plasmodium falciparum parasite clone. Each data point represents an individual IC50
value obtained from triplicate columns on each of three or five drug-coated plates, generating nine or 15 IC50 values per experiment/occasion.
For the drug stability experiment under field conditions, ODs from duplicate columns were averaged to generate a single IC50 value for each
plate, producing 26 IC50 values for 26 assays run. All individual IC50 values are presented in the “W2 Range” column. Red lines represent median
IC50s and interquartile ranges.
(a) ‘Intra-assay’ variability is assessed by% CV of IC50 values within each HRP-2 assay conducted by a single
technician on a single day. (b), (c) IC50 values measured from the same experiment were analysed in both the intra/inter-assay variability and
long-term culture variability. (d) ‘Inter-assay’ variability was assessed by the % CV of IC50 values among HRP-2 assays conducted on different days
by the same technician, while technician performance was assessed by the difference in IC50 values among technicians.
(e) IC50 values obtained
from technician 1 were significantly lower than those from technician 2 and 3.
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fluctuated between 3.0 and 6.4 nM for DHA (% CV=
29.8) and 3.0 and 6.7 nM for AS (% CV= 37.6).
The effects of drug-coated plate stability during trans-
port to/from and storage at the field on W2 IC50 were
evaluated, with 26 paired IC50 assays performed on 13
different drug-coated plate lots prior to transport, and
upon return from remote field sites after several weeks
(maximum two months) of storage on-site. Despite IC50
variability (% CV) between individual plate lots for W2
with both DHA (% CV= 37.5) and AS (% CV=49.2),
there were no statistically significant differences in IC50
values obtained from plates before going and after
returning from the field for either DHA (mean differ-
ence for DHA −0.64 nM for pairwise comparisons using
the Wilcoxon matched-pair test; p = 0.06) or AS (differ-
ence of 0.08 nM; p = 0.74, see Figure 1).
When a total of 251 W2 IC50 values generated from
all experiments were pooled, and outliers were excluded
using Grubb’s test, median IC50 of DHA was 4.1 nM
(IQR 3.5-4.7 nM), and AS was 4.2 nM (IQR 3.4-6.0 nM).
The overall IC50 range was 2.0-7.6 nM for DHA, and
2.0-9.4 nM for AS. Using the same plate lots, the median
IC50 of CQ for the W2 clone was 297.4 nM (IQR 221.3-
433.7 nM) and 21.3 nM for MQ (IQR 18.3-31.7 nM)
(Table 1). The W2 clone was resistant to CQ but suscep-
tible to mefloquine when compared to other commonly
used clones D6 and 3D7, while 3D7 was less
artemisinin-sensitive than W2 and D6 (Table 2).
Quality control of drug-coated plates was evaluated by
LC/MS of starting AS and DHA concentrations, measur-
ing the highest drug concentration in the starting wells
used to initiate serial dilutions. Variability was assessed
over a period of six months using three different lots of
drug-coated plates. Three plates per lot were randomly
selected and a total of 27 starting drug concentrations
(triplicate wells/plate) were measured (Figure 2). There
was variation in starting drug concentration between
plates for AS with 21.8% CV, and an overall median start-
ing concentration of 14.7 ng/mL compared to a nominal
target starting concentration of 20 ng/mL after addition
of sample. For DHA, the median starting concentration
was 11.9 ng/mL compared to a nominal value of 20 ng/
mL with a 13.3% CV (n = 27 for both drugs). Despite the
differences between actual and nominal starting concen-
trations, there were no statistically significant differences
in median starting concentrations between plate lots.
Artemisinin susceptibility of field Plasmodium falciparum
isolates compared to the W2 clone
The IC50 values for DHA of field isolates from an
artemisinin-resistant area in western Cambodia were
compared to the W2 reference clone used for quality
control on the same plate lots over a one-year period
from August 2008 to August 2009 [17] (Figure 3). There
were 12 lots of plates made in total for the study, with
IC50 values generated for 125 volunteers, and there were
no outlier IC50 values for the W2 parasite detected or
excluded. Despite a broad susceptibility range of the field
isolates, there was a significant increase in median IC50
for DHA (8.69 nM) compared to the W2 reference clone
(3.9 nM) both from patients with 100% parasite clear-
ance time (PCT100) ≤72 hours (6.3 nM) and >72 hours
(9.6 nM), (p < 0.0001, Mann–Whitney U test). Further-
more, the IC50 for DHA of field parasite isolates from
patients with PCT100 >72 hours was significantly higher
Table 1 Overall variation in IC50 values (nM) of DHA, AS,
MQ and CQ against the W2 clone measured from all




Median Maximum Minimum IQR
DHA 250 4.1 4.1 7.6 2.0 3.5-4.7
AS 250 4.4 4.2 9.4 2.0 3.4-6.0
MQ 248 17.7 21.3 78.1 3.2 18.3-31.7
CQ 251 304.5 297.4 779.1 116.3 221.3-433.7
Table 2 Median IC50s (with interquartile ranges) of DHA,
AS, MQ and CQ against W2, D6 and 3D7 clones in the
HRP-2 assay (N= 8 each)
IC50 DHA (nM) AS (nM) MQ (nM) CQ (nM)
W2 3.8 (2.6-3.9) 4.2 (3.2-7.1) 30.4 (11.6-46.1) 336.7 (310.3-405.1)
D6 3.9 (3.8-4.3) 5.5 (3.38-7.71) 82.7 (68.2-93.0) 16.1 (6.0-18.3)





























Lot 1       Lot 2        Lot 3        Lot 1       L ot 2       Lot 3
p = 0.31 (Kruskal-Wallis) p = 0.17 (Kruskal-Wallis)
Figure 2 Starting AS and DHA concentrations used for serial
dilutions on in vitro drug culture plate lots for the HRP-2 assay.
The dashed line indicates the nominal final starting concentration of
20 ng/mL after addition of sample for both drugs. Red lines indicate
medians and interquartile ranges for drug concentration. From three
drug-coated plate lots, a total of 27 starting wells collected were
measured (three wells/plate x three plates/lot).
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than PCT100 ≤72 hours (p = 0.0134). Similarly, median
field isolate IC50s for AS were significantly higher than
those for the W2 clone (p < 0.0001, Mann–Whitney U
test), and there were significant differences between
PCTs greater than or less than 72 hours (6.0 nM vs 5.4
nM, p = 0.039).
Discussion
The value of using an artemisinin-susceptible W2 clone to
control for the inherent variability in the HRP-2 in vitro
assay was demonstrated here, particularly with field iso-
lates, defining a range for drug susceptibility assay per-
formance. By comparing field isolates with a reference
clone used for the same plate lots, a clear determination
of a reduction in drug susceptibility in an area of reported
drug resistance in Cambodia can be attained. This ap-
proach has significant public health utility, allowing mean-
ingful comparisons of field isolates populations, and
controlling for variability in assay conditions. Although in-
dividual or even collective IC50 values may offer little in
predicting the onset of drug resistance in a community
due to wide variability and differences in assay methods
and conditions, comparison with a well-characterized
clone mitigated some of these limitations on assay inter-
pretation. The use of a reference clone to directly measure
reproducibility of IC50 values on plates used to assess field
isolates may be particularly valuable in accounting for
variability due to technique, providing more meaningful
inter-laboratory and multi-site surveillance comparisons.
The inherent variability of the HRP-2 ELISA-based IC50
assay was quantified and variation in drug concentrations
between different plates was found to be an important
source of assay variability, confirmed by LC/MS analysis of
plate concentrations. While a significant difference in start-
ing drug concentrations between plate-coating lots was not
observed, actual drug concentrations recovered from the
plates by LC/MS were generally below nominal concentra-
tions, indicating that final IC50 may have been overesti-
mated. Greater variation in AS plate concentrations
observed compared to DHA may explain somewhat higher
variability in AS IC50 values compared to DHA. Unlike
DHA, the variation seen could be explained by the fact that
AS (an esterified butanedioic acid) is readily hydrolyzed to
DHA and succinic acid in aqueous solution. Inherent assay
variability provides additional impetus to standardize meth-
ods wherever possible, and index results to a reference
clone. Methods to improve the reproducibility and preci-
sion of drug dilutions (e g, use of a pipetting robot,
improved stabilizing techniques, or plates with materials
that drug substance is unlikely to adhere to) may have the
greatest impact on further improving assay reliability. There
was significant day-to-day inter-assay IC50 variability for
individual technicians (% CV >30 for AS), as well as differ-
ences in performance between technicians. Some degree of
difference attributable to manual performance of laboratory
techniques is expected. Understanding this variability helps
to further define the performance range of this assay, and
further supports interpretation of field isolate values.
Freeze/thaw cycles, and long-term culture of the W2
clone were less important sources of assay variability, as
IC50 values generated during culture time/freeze-thaw
cycles fluctuated within the assay performance range.
Despite an increase in IC50 values at month 3 and 4,
variability was no greater than that seen between assays
performed by the same technician on different days (in-
ter-assay variability), and values at month 5 returned to
baseline, suggesting that there were no time-dependent
changes in W2 IC50 values arising from long-term con-
tinuous culture. Transport and storage of drug plates in
field conditions did not account for substantial variabil-
ity, with no difference in W2 IC50 values obtained before
and after transport to the field, supporting the utility of
the HRP-2 method at remote field sites. Unmeasured
variability in assay conditions and parasite characteristics
may also have contributed. Understanding the inherent
variability of the assay, and defining performance ranges
of reference parasite clones, are important for laborator-
ies conducting drug susceptibility assays on field isolates.
A reference clone may further be useful in overcoming
issues of sampling bias originating from two sources in












W2 parasite PCT 100 ≤ 72 hrs. PCT 100  >72 hrs.
1
(N= 67) (N=62) (N=63)
Figure 3 IC50 values of DHA against clinical Plasmodium
falciparum field isolates collected from a drug-resistant area in
Cambodia (middle and right hand columns), compared to the
W2 parasite used as a reference clone (left hand column).
Median and interquartile ranges are shown. Median IC50s of DHA
were significantly higher for patients with PCT100 >72 hours (9.6 nM)
than PCT100 ≤72 hours (6.3 nM, p = 0.0134), and both were
significantly higher than the reference W2 clone (3.9 nM, p< 0.0001).
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from in vitro/ex vivo clinical isolate studies are gener-
ally derived from clinical trials or dedicated parasite
sampling studies. However, in both cases, systematic
sampling methods (e g, randomized household cluster
surveys) are rarely employed, instead relying on con-
venience sampling from particular clinics or communi-
ties, or retrospective reviews of sample collection efforts
from multiple sites and/or laboratories. Recovery of mal-
aria isolates from culture, and interpretability of parasite
growth curves are other potential sources of sampling
bias, with the proportion of evaluable samples as low as
50-60% in some cases. Low parasitaemia samples are
particularly problematic, and the effects on point esti-
mates of ‘resistance’ can be problematic due to the
unmeasurable impact of non-recovery on population
values. By establishing a susceptibility baseline, compari-
son with a reference clone mitigates these uncertainties
to some extent, facilitating sample comparisons at the
population level.
While the W2 clone showed similar trends against
W2, D6 and 3D7 in our hands to those previously
reported in the HRP-2 assay, the values were not identi-
cal, underscoring the need for standardization within
and among laboratories. Each in vitro assay system has
limitations. Because of its high sensitivity, HRP-2 is used
as a parasite detection method in several rapid diagnos-
tic test kits [24], and has even been advocated for use in
a salivary detection test [25]. HRP-2 is a by-product of
parasite metabolism that persists in blood following mal-
aria infection and treatment, making it a poor prognostic
indicator. Differences in metabolic conditions during the
culture process could potentially confound the interpret-
ation of in vitro assay results [26]. The HRP-2 in vitro
drug sensitivity method presented here has been advo-
cated in populations with low transmission rates, low or
fluctuating parasite densities, and chronic infections,
and is considered to be acceptable for use in Southeast
Asia for these reasons [5,27]. Some have suggested that
the SYBR Green I method’s specificity in whole blood
may be confounded by the presence of human DNA,
limiting its utility in clinical isolates [28]. However, a re-
cent report from Kenya found SYBR Green I to be a sen-
sitive, cost-effective method for field use, and IC50 values
compared well with historic parasite data using the triti-
ated hypoxanthine method [12]. Even with the long-
accepted “gold standard” hypoxanthine method, wide
variability in field isolate values has been reported, most
recently in a published review of in vitro data collected
from drug efficacy trials in Cambodia over seven years.
While the large sample size allowed detection of discern-
ible differences in drug susceptibility between specimens
collected in the eastern and western portions of the
country, such extensive collection efforts may not be
feasible in all settings [29].
The reference clone provides a higher level of assur-
ance in the validity and comparability of smaller data
sets, and allows for monitoring of trends over shorter
periods to support timely public health action, including
shifts in drug treatment policy. Comparing changes in
field isolate IC50s indexed to a well-characterized refer-
ence clone that demonstrates within-laboratory reprodu-
cibility is recommended. For an assay to have public
health utility, the choice of methodology is less import-
ant than demonstrated experience with the system, use
of a well-characterized reference clone, and most im-
portantly, establishment of reproducible methods.
Conclusions
The use of standardized P. falciparum reference clones
to provide context for variability among several assay
systems is a key in harmonizing regional laboratories for
in vitro/ex vivo drug susceptibility monitoring. Quantify-
ing inherent assay variability and establishing a drug sus-
ceptibility range of the reference P. falciparum clone
permitted meaningful data comparisons and improved
the interpretability of field isolate susceptibility.
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